The global IPV vaccines market is estimated to be valued at USD 199.9 Mn in 2025 and expected to reach at USD 358.5 Mn by 2032 With a CAGR of 8.7% during the forecast period (2025-2032). Coherent ...

In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

GlaxoSmithKline was formerly called ... Norwich Union and CGU plc, and is the 14th largest insurance company in the world. British American Tobacco is the world’s 2nd largest cigarette ...

Takeda Pharmaceutical Company Limited engages in the research ... It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine ...

Clinigen, the global specialist pharmaceutical services Group, has appointed seasoned biopharma executive Paul Carter as Non-Executive Chair of its Board. This appointment strengthens the Board and ...

Is a longevity pill on the horizon? Harvard Medical School professor David Sinclair certainly thinks so – while staring down ...

The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company. The Swiss pharma group said ...